Article Versions Notes

Goya T, Imoto K, Tashiro S, Aoyagi T, Takahashi M, Kurokawa M, Suzuki H, Tanaka M, Kato M, Kohjima M, et al. The Efficacy of Tofogliflozin on Metabolic Dysfunction-Associated Fatty Liver Disease. Gastroenterology Insights. 2022; 13(1):20-26. https://doi.org/10.3390/gastroent13010003

Goya, Takeshi, Koji Imoto, Shigeki Tashiro, Tomomi Aoyagi, Motoi Takahashi, Miho Kurokawa, Hideo Suzuki, Masatake Tanaka, Masaki Kato, Motoyuki Kohjima, and et al. 2022. "The Efficacy of Tofogliflozin on Metabolic Dysfunction-Associated Fatty Liver Disease" Gastroenterology Insights 13, no. 1: 20-26. https://doi.org/10.3390/gastroent13010003

Goya, T., Imoto, K., Tashiro, S., Aoyagi, T., Takahashi, M., Kurokawa, M., Suzuki, H., Tanaka, M., Kato, M., Kohjima, M., & Ogawa, Y. (2022). The Efficacy of Tofogliflozin on Metabolic Dysfunction-Associated Fatty Liver Disease. Gastroenterology Insights, 13(1), 20-26. https://doi.org/10.3390/gastroent13010003